JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 40 No. 7 1125-1131
© 1999 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sugawara, Y.
Right arrow Articles by Wahl, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sugawara, Y.
Right arrow Articles by Wahl, R. L.

Evaluation of FDG PET in Patients with Cervical Cancer

Yoshifumi Sugawara, Avraham Eisbruch, Shigeru Kosuda, Betty E. Recker, Paul V. Kison and Richard L. Wahl

Departments of Internal Medicine, Radiation Oncology and Radiology, Division of Nuclear Medicine, University of Michigan Medical Center, Ann Arbor, Michigan

Correspondence: For correspondence or reprints contact: Richard L. Wahl, MD, Division of Nuclear Medicine, University of Michigan Medical Center, 1500E Medical Center Dr., B1G505C, Box 0028, Ann Arbor, MI 48109.

ABSTRACT

Although many human cancers can be imaged by 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) and PET, there is little clinical experience with FDG PET in cervical cancer. The purpose of this study was to evaluate the feasibility of FDG PET scans on patients with cervical cancer. Methods: FDG PET scans were performed on 21 patients with histologically proven uterine cervical cancer (17 newly diagnosed, 4 recurrence). After two levels of transmission scanning, approximately 370 MBq FDG were injected, and dynamic scans over 60 min were obtained at the level of suspected tumors, followed by static scans. Postvoid scans were also obtained in 11 patients to minimize FDG activity in the urinary bladder. FDG uptake was interpreted visually and classified into 4 grades (0 = normal, 1 = probably normal, 2 = probably abnormal and 3 = definitely abnormal). For a semiquantitative index of FDG uptake in tumors, the standardized uptake value (SUV) corrected by predicted lean body mass (SUL) was calculated and compared. The detectability of lymph node metastases by PET was compared with that by CT. Results: Of the 21 newly diagnosed or recurrent cancers, 16 (76%) were detected by FDG PET without use of postvoid imaging (i.e., interpreted as grade 2 or 3). The SULs of tumors ranged from 2.74–13.03, with a mean of 8.15 ± 3.00 (SUV range 3.68–14.94, mean 10.31 ± 3.19). There was no significant relationship between the SUL of cervical cancer and the clinical stage. Postvoid FDG PET images substantially reduced the tracer activity in the urinary bladder and improved the visualization of cervical cancers, with three additional cases detected using the postvoid images. In the 11 patients with postvoid imaging, all 11 cancers (100%) were detected. FDG PET detected lymph node metastases in 6 (86%) of 7 patients with known metastases, whereas CT was positive in 4 patients (57%), equivocal in 2 patients (29%) and negative in 1 patient (14%). All PET and CT scans were true-negative in the patients with no lymph node metastases (interpreted as grade 0 or 1 by PET, and as negative by CT). Conclusion: These preliminary data demonstrate the feasibility of FDG PET imaging in patients with cervical cancer. FDG PET appears to be promising for detecting untreated or recurrent cervical cancers and lymph node metastases, although the excreted FDG in the urine remains problematic in some cases.

Key Words: cervical cancer • 18F-fluoro-2-deoxy-D-glucose • PET




This article has been cited by other articles:


Home page
Am. J. Roentgenol.Home page
K. Kitajima, K. Murakami, E. Yamasaki, I. Fukasawa, N. Inaba, Y. Kaji, and K. Sugimura
Accuracy of 18F-FDG PET/CT in Detecting Pelvic and Paraaortic Lymph Node Metastasis in Patients with Endometrial Cancer
Am. J. Roentgenol., June 1, 2008; 190(6): 1652 - 1658.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
D. A. Anjos, E. C.S.C. Etchebehere, C. D. Ramos, A. O. Santos, C. Albertotti, and E. E. Camargo
18F-FDG PET/CT Delayed Images After Diuretic for Restaging Invasive Bladder Cancer
J. Nucl. Med., May 1, 2007; 48(5): 764 - 770.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
V. Gregoire, K. Haustermans, X. Geets, S. Roels, and M. Lonneux
PET-Based Treatment Planning in Radiotherapy: A New Standard?
J. Nucl. Med., January 1, 2007; 48(1_suppl): 68S - 77S.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
H.-H. Chou, T.-C. Chang, T.-C. Yen, K.-K. Ng, S. Hsueh, S.-Y. Ma, C.-J. Chang, H.-J. Huang, A. Chao, T.-I Wu, et al.
Low Value of [18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Primary Staging of Early-Stage Cervical Cancer Before Radical Hysterectomy
J. Clin. Oncol., January 1, 2006; 24(1): 123 - 128.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
S. Sironi, A. Buda, M. Picchio, P. Perego, R. Moreni, A. Pellegrino, M. Colombo, C. Mangioni, C. Messa, and F. Fazio
Lymph Node Metastasis in Patients with Clinical Early-Stage Cervical Cancer: Detection with Integrated FDG PET/CT
Radiology, December 1, 2005; 238(1): 272 - 279.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
T. Z. Belhocine
18F-FDG PET Imaging in Posttherapy Monitoring of Cervical Cancers: From Diagnosis to Prognosis
J. Nucl. Med., October 1, 2004; 45(10): 1602 - 1604.
[Full Text] [PDF]


Home page
RadiologyHome page
E. M. Rohren, T. G. Turkington, and R. E. Coleman
Clinical Applications of PET in Oncology
Radiology, May 1, 2004; 231(2): 305 - 332.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
C. Scarfone, W. C. Lavely, A. J. Cmelak, D. Delbeke, W. H. Martin, D. Billheimer, and D. E. Hallahan
Prospective Feasibility Trial of Radiotherapy Target Definition for Head and Neck Cancer Using 3-Dimensional PET and CT Imaging
J. Nucl. Med., April 1, 2004; 45(4): 543 - 552.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
R. L. Wahl
Why Nearly All PET of Abdominal and Pelvic Cancers Will Be Performed as PET/CT
J. Nucl. Med., January 1, 2004; 45(90010): 82S - 95.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
S.-Y. Ma, L.-C. See, C.-H. Lai, H.-H. Chou, C.-S. Tsai, K.-K. Ng, S. Hsueh, W.-J. Lin, J.-T. Chen, and T.-C. Yen
Delayed 18F-FDG PET for Detection of Paraaortic Lymph Node Metastases in Cervical Cancer Patients
J. Nucl. Med., November 1, 2003; 44(11): 1775 - 1783.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T.-C. Yen, K.-K. Ng, S.-Y. Ma, H.-H. Chou, C.-S. Tsai, S. Hsueh, T.-C. Chang, J.-H. Hong, L.-C. See, W.-J. Lin, et al.
Value of Dual-Phase 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Cervical Cancer
J. Clin. Oncol., October 1, 2003; 21(19): 3651 - 3658.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
T. Torizuka, T. Kanno, M. Futatsubashi, H. Okada, E. Yoshikawa, F. Nakamura, M. Takekuma, M. Maeda, and Y. Ouchi
Imaging of Gynecologic Tumors: Comparison of 11C-Choline PET with 18F-FDG PET
J. Nucl. Med., July 1, 2003; 44(7): 1051 - 1056.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
T. Yoshioka, K. Yamaguchi, K. Kubota, T. Saginoya, T. Yamazaki, T. Ido, G. Yamaura, H. Takahashi, H. Fukuda, and R. Kanamaru
Evaluation of 18F-FDG PET in Patients with Advanced, Metastatic, or Recurrent Gastric Cancer
J. Nucl. Med., May 1, 2003; 44(5): 690 - 699.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
S.-Y. Ryu, M.-H. Kim, S.-C. Choi, C.-W. Choi, and K.-H. Lee
Detection of Early Recurrence with 18F-FDG PET in Patients with Cervical Cancer
J. Nucl. Med., March 1, 2003; 44(3): 347 - 352.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
K. Koyama, T. Okamura, J. Kawabe, N. Ozawa, K. Torii, N. Umesaki, M. Miyama, H. Ochi, and R. Yamada
Evaluation of 18F-FDG PET with Bladder Irrigation in Patients with Uterine and Ovarian Tumors
J. Nucl. Med., March 1, 2003; 44(3): 353 - 358.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
T. R. Miller, E. Pinkus, F. Dehdashti, and P. W. Grigsby
Improved Prognostic Value of 18F-FDG PET Using a Simple Visual Analysis of Tumor Characteristics in Patients with Cervical Cancer
J. Nucl. Med., February 1, 2003; 44(2): 192 - 197.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
B. A. Siegel, L. P. Adler, R. L. Wahl, A. Williams, N. DeSouza, and A. M. Peters
FDG Positron Emission Tomography Detection of Pelvic Nodal Metastases in Gynecologic Cancer
Am. J. Roentgenol., March 1, 2002; 178 (3): 762 - 764.
[Full Text] [PDF]


Home page
JCOHome page
P. W. Grigsby, B. A. Siegel, and F. Dehdashti
Lymph Node Staging by Positron Emission Tomography in Patients With Carcinoma of the Cervix
J. Clin. Oncol., September 1, 2001; 19(17): 3745 - 3749.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. S. Silverman, R. E. Coleman, and M. E. Phelps
A Tabulated Summary of the FDG PET Literature
J. Nucl. Med., May 1, 2001; 42(90050): 1S - 93.
[Full Text] [PDF]


Home page
RadiologyHome page
M. J. Reinhardt, C. Ehritt-Braun, D. Vogelgesang, C. Ihling, S. Högerle, M. Mix, E. Moser, and T. M. Krause
Metastatic Lymph Nodes in Patients with Cervical Cancer: Detection with MR Imaging and FDG PET
Radiology, March 1, 2001; 218(3): 776 - 782.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1999 by the Society of Nuclear Medicine.